NG
DXCM icon

Novem Group’s DexCom DXCM Stock Holding History

Novem Group’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,184
Closed -$969K – 414
2025
Q1 		$969K Buy
14,184
+3,321
+31% +$271K 0.14% 144
2024
Q4 		$845K Buy
+10,863
New +$804K 0.12% 144

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Novem Group's DXCM Position: Q2 2025 in Review

Novem Group sold out of DexCom (DXCM) in Q2 2025, closing a stake of 14,184 shares — an estimated $969K sold.

Novem Group first reported a position in DXCM in Q4 2024 and held it in 2 quarters. The position peaked at $969K in Q1 2025. 939 funds tracked by Wall St. Rank hold DXCM as of Q2 2025.

  • Novem Group reported no remaining DexCom position as of Q2 2025 after selling out during the quarter.
  • Novem Group sold 14,184 DexCom shares in Q2 2025, an estimated $969K.
  • Novem Group first reported a position in DexCom in Q4 2024 and held it in 2 quarters.
  • Novem Group's DexCom position peaked at $969K in Q1 2025.
  • 939 funds tracked by Wall St. Rank held DexCom as of Q2 2025.

Based on Novem Group's 13F filing for Q2 2025, filed 16 Jul 2025.